



gskimi

FIRST OF A KIND

Our Reading, UK, operation has recently completed the design and construction of a multi-stage continuous active pharmaceutical ingredient (API) manufacturing facility for GlaxoSmithKline's chemical development pilot plant at Stevenage in the UK.



This ground-breaking facility, incorporating process intensification techniques, and supported by the latest in process analytical technology, is believed to be the first of its kind in the pharmaceutical industry.

The plant, referred to as the Innovative Manufacturing Initiative (IMI) facility, has been designed as a series of sixteen factory-built, modular, pre-assembled units.

Neatly accommodated on two working levels of the existing plant, which provides gravity flow options, the units are served by utility supplies from the existing and adjacent pilot plant facilities.

The modular assembly incorporates the concept of 'plug-and-play', which allows for easy connection of utilities and services to each of the modules.

The modules are also portable and re-configurable, allowing the IMI unit to be multi-purpose.

This cutting-edge facility is expected to form the basis for scale-up of the IMI technology into the full-scale manufacture of new chemical entities.

Using continuous processing rather than batch manufacture, this new facility offers significant savings in capital and operating costs, compared with a conventional bulk manufacturing plant.

Foster Wheeler is delighted to have played a key role in this significant step forward in API manufacture.

Pharma *i*

Download our new continuous processing flyer:
<http://www.fwc.com/publications/brochures>